Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AdvanTIG-206: Ociperlimab + Tislelizumab + BAT1706 in Advanced HCC
NCT04948697Phase 2Completed
- Sponsor
- BeiGene
- Start
- Aug 2021
- Primary completion
- Feb 2024
- Modality
- IgG Antibodies, Immune Checkpoint Inhibitors
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial of ociperlimab in hepatocellular carcinoma (HCC) (2 arms), sponsored by BeiGene. Primary endpoint: Objective Response Rate up to 27 months. Started Aug 2021; status: completed.
02
Drugs
ociperlimab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT04948697.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04948697.